Table 1.

In vivo effects of rituximab-engineered NP samples

TreatmentsSurvival (median), dP (vs. controls)P (vs. Nutlin-3 or NP-Rt)
Controls15–16.5
Nutlin-3210.3650
NP-Nut27.50.0088c0.047a,c
NP-Rt250.0027c
NP-Rt-Nut360.0008c0.041b,c

NOTE: P was calculated on the basis of Gehan–Breslow–Wilcoxon test.

  • aCompared with Nutlin-3.

  • bCompared with NP-Rt.

  • cStatistically significant.